De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
874 Overzicht aandelen
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited onderzoekt, ontwikkelt, produceert en verkoopt samen met zijn dochterondernemingen Chinese patentgeneesmiddelen en westerse geneesmiddelen, chemische grondstoffen, natuurlijke en biologische geneesmiddelen en tussenproducten van chemische grondstoffen in de Volksrepubliek China en internationaal.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 3/6 |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | HK$21.45 |
| 52 Week Hoogtepunt | HK$24.20 |
| 52 Week Laag | HK$16.62 |
| Bèta | 0.55 |
| 11 maand verandering | 21.05% |
| 3 maanden verandering | 5.41% |
| 1 Jaar Verandering | -1.61% |
| 33 jaar verandering | 8.33% |
| 5 jaar verandering | -20.11% |
| Verandering sinds IPO | 1,500.75% |
Recent nieuws en updates
Here's What's Concerning About Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns On Capital
Sep 25
Earnings Report: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed Revenue Estimates By 8.1%
Sep 04Recent updates
Here's What's Concerning About Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns On Capital
Sep 25Earnings Report: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed Revenue Estimates By 8.1%
Sep 04A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Jul 15Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26Rendement voor aandeelhouders
| 874 | HK Healthcare | HK Markt | |
|---|---|---|---|
| 7D | 10.0% | 10.6% | 9.6% |
| 1Y | -1.6% | -19.9% | 27.2% |
Rendement versus industrie: 874 overtrof de Hong Kong Healthcare industrie, die het afgelopen jaar een rendement -21.9 % opleverde.
Rendement versus markt: 874 presteerde slechter dan Hong Kong Market, dat het afgelopen jaar een rendement van 19.7 % opleverde.
Prijsvolatiliteit
| 874 volatility | |
|---|---|
| 874 Average Weekly Movement | 4.7% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in HK Market | 17.4% |
| 10% least volatile stocks in HK Market | 3.8% |
Stabiele aandelenkoers: 874 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van 874 is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1997 | 28,760 | Hong Li | www.gybys.com.cn |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited onderzoekt, ontwikkelt, produceert en verkoopt samen met zijn dochterondernemingen Chinese patentgeneesmiddelen en westerse geneesmiddelen, chemische grondstoffen, natuurlijke en biologische geneesmiddelen en tussenproducten van chemische grondstoffen in de Volksrepubliek China en internationaal. Het bedrijf is actief via de segmenten Great Southern TCM, Great Commerce, Great Health en Overige. Het bedrijf is ook betrokken bij de groothandel, detailhandel, verkoop, import en export van westerse en Chinese geneesmiddelen, medische instrumenten, farmaceutische producten, medische apparatuur en gezondheidsproducten; en onderzoek en ontwikkeling, productie en verkoop van dranken, voedingsmiddelen, gezondheidsproducten en andere producten; en productie en verkoop van voorverpakt voedsel, zuivelproducten, enz.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Samenvatting
| 874 fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | HK$51.93b |
| Inkomsten(TTM) | HK$4.18b |
| Inkomsten(TTM) | HK$84.30b |
8.4x
Koers/Winstverhouding0.4x
P/S-verhoudingIs 874 overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| 874 resultatenrekening (TTM) | |
|---|---|
| Inkomsten | CN¥76.59b |
| Kosten van inkomsten | CN¥62.98b |
| Brutowinst | CN¥13.61b |
| Overige uitgaven | CN¥9.81b |
| Inkomsten | CN¥3.79b |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
Oct 26, 2024
| Winst per aandeel (EPS) | 2.33 |
| Brutomarge | 17.77% |
| Nettowinstmarge | 4.95% |
| Schuld/Eigen Vermogen Verhouding | 34.5% |
Hoe presteerde 874 op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
4.1%
Huidig dividendrendement49%
UitbetalingsratioBetaalt 874 een betrouwbaar dividend?
Zie 874 dividendgeschiedenis en benchmarks| Guangzhou Baiyunshan Pharmaceutical Holdings dividenddata | |
|---|---|
| Ex Dividend Datum | Oct 15 2024 |
| Betaaldatum dividend | Nov 15 2024 |
| Dagen tot Ex-dividend | 8 days |
| Dagen tot dividendbetaaldatum | 39 days |
Betaalt 874 een betrouwbaar dividend?
Zie 874 dividendgeschiedenis en benchmarks